Abstract
Background Stroke leads to complex chronic structural and functional brain changes that specifically affect motor outcomes. The brain-predicted age difference (brain-PAD) has emerged as a sensitive biomarker. Our previous study showed higher global brain-PAD associated with poorer motor function post-stroke. However, the relationship between local stroke lesion load, regional brain age, and motor impairment remains unclear.
Methods We studied 501 individuals with chronic unilateral stroke (>180 days post-stroke) from the ENIGMA Stroke Recovery Working Group dataset (34 cohorts). Structural T1-weighted MRI scans were used to estimate regional brain-PAD in 18 predefined functional subregions via a graph convolutional network algorithm. Lesion load for each region was calculated based on lesion overlap. Linear mixed-effects models assessed associations between lesion size, local lesion load, and regional brain-PAD. Machine learning classifiers predicted motor outcomes using lesion loads and regional brain-PADs. Structural equation modeling examined directional relationships among corticospinal tract lesion load (CST-LL), ipsilesional brain-PAD, motor outcomes, and contralesional brain-PAD.
Findings Larger total lesion size was positively associated with higher ipsilesional regional brain-PADs (older brain age) across most regions (p□<□0.05), and with lower contralesional brain-PAD, notably in the ventral attention-language network (p□<□0.05). Higher local lesion loads showed similar patterns. Specifically, lesion load in the salience network significantly influenced regional brain-PADs across both hemispheres. Machine learning models identified CST-LL, salience network lesion load, and regional brain-PAD in the contralesional frontoparietal network as the top three predictors of motor outcomes. Structural equation modeling revealed that larger stroke damage was associated with poorer motor outcomes (β□=□-0.355, p□<□0.001), which were further linked to younger contralesional brain age (β□=□0.204, p□<□0.001), suggesting that severe motor impairment is linked to compensatory decreases in contralesional brain age.
Interpretation Our findings reveal that larger stroke lesions are associated with accelerated aging in the ipsilesional hemisphere and paradoxically decelerated brain aging in the contralesional hemisphere, suggesting compensatory neural mechanisms. Assessing regional brain age may serve as a biomarker for neuroplasticity and inform targeted interventions to enhance motor recovery after stroke.
Fundings Micheal J Fox Foundation, National Institutes of Health, Canadian Institutes of Health Research, National Health and Medical Research Council, Australian Brain Foundation, Wicking Trust, Collie Trust, and Sidney and Fiona Myer Family Foundation, National Heart Foundation, Hospital Israelita Albert Einstein, Australian Research Council Future Fellowship, Wellcome Trust, National Institute for Health Research Imperial Biomedical Research Centre, European Research Council, Deutsche Forschungsgemeinschaft, REACT Pilot, National Resource Center, Research Council of Norway, South-Eastern Norway Regional Health Authority, Norwegian Extra Foundation for Health and Rehabilitation, Sunnaas Rehabilitation Hospital HT, University of Oslo, and VA Rehabilitation Research and Development
Competing Interest Statement
S. C. Cramer is a consultant for Constant Therapeutics, BrainQ, Myomo, MicroTransponder, Panaxium, Beren Therapeutics, Medtronic, Stream Biomedical, NeuroTrauma Sciences, and TRCare; C. A. Hanlon served as a consultant to MagStim, Roswell Park Cancer Insitute, and is an employee of BrainsWay; G. F. Wittenberg serves on the medical advisory boards for Myomo and NeuroInnovators; The other authors report no disclosures relevant to the manuscript.
Funding Statement
G. Park was supported by Micheal J Fox Foundation (MJFF) - The Parkinson's Progression Markers Initiative (PPMI) #MJFF-023385. M. Khan and S.-L. Liew were supported by the National Institutes of Health (NIH) grant R01 NS115845. L. Boyd was supported by Canadian Institutes of Health Research (CIHR) Operating grants (MOP-130269; MOP-106651) and Project grant (PTJ-148535) PI L.A.B. A. Brodtmann was supported by a National Health and Medical Research Council project grant GNT1020526, the Australian Brain Foundation, Wicking Trust, Collie Trust, and Sidney and Fiona Myer Family Foundation, as well as fellowships from the National Heart Foundation 100784 and 104748. C. Buetefisch was supported by NIH grant (R01NS090677). A. B. Conforto was supported by Hospital Israelita Albert Einstein 2250-14, and NIH R01NS076348-01. N. Egorova-Brumley was supported by the Australian Research Council Future Fellowship FT230100235. F. Geranmayeh was supported by the Wellcome Trust (093957), and partly supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre. C. A. Hanlon was supported by NIH/National Institute of General Medical Sciences (NIGMS) grant (P20GM109040). S. Kautz was supported by NIH grant GM109040. K. Revill was supported by NIH grant (R01NS090677). N. J. Seo was supported by grants from the NIH/National Institute of Child Health and Human Development (NICHD) (R01HD094731) and NIH/NIGMS (P20GM109040). S. Soekadar was supported by European Research Council (ERC NGBMI 759370), Deutsche Forschungsgemeinschaft (DFG) grant SO 932/7-1. G. Thielman was supported by the REACT Pilot Grant sub-award for "The effect of transcranial direct current stimulation (tDCS) on upper extremity use following a Cerebral Vascular Accident (CVA)" and the National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation: Pilot Projects Component 2019-2021, Primary Investigator. D. Vecchio was supported by RC-24. L. T. Westlye was supported by the Research Council of Norway [249795, 248238], the South-Eastern Norway Regional Health Authority [2014097, 2015044, 2015073, 2018037, 2018076, 2019107, 2020086], the Norwegian Extra Foundation for Health and Rehabilitation [2015/ FO5146], Sunnaas Rehabilitation Hospital HT, and the Department of Psychology, University of Oslo. L.T. Westlye performed this work on the Services for sensitive data (TSD), University of Oslo, Norway, with resources provided by UNINETT Sigma2 - the National Infrastructure for High-Performance Computing and Data Storage in Norway. G. F. Wittenberg was supported by grants from the VA Rehabilitation Research and Development program and the NIH/National Institute of Neurological Disorders and Stroke (NINDS). H. Kim was supported by NIH grant (#U01 AG024904).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The collection of ENIGMA stroke data followed the Declaration of Helsinki and was approved by local ethics boards at each respective institute. All participants provide written informed consent for the study. This study was approved by the Institutional Review Board (IRB# 00002881) at the University of Southern California Health Science Campus. The UKB data used for our study was anonymous and deidentified, exempting the study from the requirement of obtaining informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
UK Biobank data is available by request to the UK Biobank group (https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access). ENIGMA Stroke Recovery data is available by request to the ENIGMA Stroke Recovery group (https://enigma.ini.usc.edu/ongoing/enigma-stroke-recovery/), subject to local PI approval and compliance with all relevant regulatory boards.
